Business mix
- Galleri test: multi-cancer early detection from a blood sample is the core product.
- Clinical evidence: studies, real-world data, and physician adoption determine credibility and guideline potential.
- Commercial access: self-pay, employer and health-system partnerships, reimbursement, and lab capacity drive revenue conversion.
Current key questions
- Do clinical data, false-positive/false-negative performance, and diagnostic pathways win physician and payer confidence?
- Can regulatory approval, reimbursement, and guideline inclusion support broad adoption?
- Is cash burn manageable while the company scales commercial access and test volume?